echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Solution agent market first broke 20 billion 3 major domestic brands skyrocketed!

    Solution agent market first broke 20 billion 3 major domestic brands skyrocketed!

    • Last Update: 2020-07-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    According to the latest data from Minnet.com, the market size of China's terminal chemical solution agent in public medical institutions in 2019 will be the first to break 20 billion, with a growth rate of 12.35 percent, higher than the 5.77 percent growth rate of the overall size of chemical drugsThe threshold of top20 brand top20 for internal service solution agent has risen to 235 million yuan, with the growth rate of three domestic brands exceeding 30%From June to date, Enhua Pharmaceuticals' hydrochloric acid midazolam syrup 3 types of imitation listing application sat in CDE acceptance, approved is expected to become the first domestic imitation, in addition, there is a left ethyl Lacitan oral solution 4 class generic listing application seisied, these new products are approved to enter the market will also become a chemical solution solution market emerging forcesFigure 1: Annual sales of solution agent (units: 10,000 yuan)According to The Net, the total size of end-of-the-line chemicals in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) reached 1092.9 billion yuan in 2019, a growth rate of 5.77 percent, the lowest in recent yearsIn terms of dosage form, injections, tablets are still in the hundreds of billions of ladders, the growth rate is 3.27%, 7.66%, 10 billion ladders involved in the dosage form including capsules, inhalers, solutions, dispersants and granules, the fastest growth rate is bulk and granules, up to 21.88 percent, solution agent growth rate of 12.35 percent, the first time in 2019 the size of 20 billion yuanTable 1: 2019 to take the solution agent brand TOP20Internal take solution agent brand TOP20, involving 5 general nutrition products, cough and cold medication has 3, vitamins, constipation drugs each have 2from the growth rate, there are 5 brands growth rate of more than 20%, including Zhejiang Iwu biological dust droplets, Zhejiang Kant Pharmaceutical Group's ammonia minga dry suspension, National Pharmaceutical Holdings Star Shark Pharmaceutical (Xiamen) vitamin D drops growth rate is more than 30%Figure 2: Annual sales trend of dust droplets from Zhejiang Wu biological (units: 10,000 yuan)Dust droplets are the exclusive products of my martial arts, used in the allergic rhinitis caused by dust tick allergy, allergic asthma desensitization treatmentIn recent years, with the increase of air pollution, the incidence of allergic rhinitis, allergic asthma continued to increase, dust droplets as the current domestic standardized under the tongue of the original desensitization agent, the demand continues to climb, in 2019 in China's public medical institutions terminal sales have exceeded 600 million yuan, ranking from 2015 TOP14 all the way up to 2019 TOP5According to the company's annual report data show that the dust droplets increase indications "used for dust aphid allergy caused by the desensitization of dermatitis treatment" Phase III clinical is under way, the future market potential is still considerableFigure 3: Zhejiang Kant Pharmaceutical Group's annual sales trend of ammonia hemp-meme dry suspension agent (units: 10,000 yuan)Aminopol methane dry suspension agent is the exclusive product of Zhejiang Kant Pharmaceutical Group, for cough and cold medicine, suitable for the relief of children's common cold and influenza caused by fever, headache, limb pain, sneezing, runny nose, nose plug, cough, sore throat and other symptomsSales of the product exceeded the 200 million yuan mark in 2019, with a growth rate of 33.92%table 2 : Internally administered solution approved from 2020 to the present Minne net data show that by 2020 so far, five new products of internal stake solution agent have been approved for listing In 2019, in the terminal of public medical institutions in China, the sales of oral solution of zusititriline hydrochloride exceeded 100 million yuan, 8 enterprises were approved; Approved, sales of more than 70 million yuan in 2019, Zucanitin oral solution sales of more than 250 million yuan, approved enterprises have 8 (including 1 import), hydrochloric acid ambromino oral solution sales of more than 580 million yuan, approved enterprises have 33 (including 2 imports) Sichuan Otsuka Pharmaceuticals' hydrochloric acid zositrice oral solution, Jianmin Group Yekai Thai medicine (with state) of the left ethyl lasitan oral solution approved according to the new classification approved as the same through consistency evaluation Sodium valproate oral solution, zokanitin oral solution, hydrochloric acid ampicinoso oral solution 3 products are currently no enterprise evaluation Table 3: The internal serving solution agent that has been passed or treated as the same as now
    As of June 8, 2020, the current number of internal service solution approvals has reached 7, with the exception of Hainan First Sound Pharmaceuticals head spore clodry suspension agent, the rest are approved according to the new classification Cephalocodry suspension, calcium gluconate zinc oral solution, alypone oral solution, hydrochloric acid zositilline oral solution and compound calcium gluconate oral solution are currently only 1 enterprise rated CDE official website data show that Enhua Pharmaceuticals hydrochloric acid Midazolam syrup 3 types of imitation listing application was recently accepted by CDE, Midazolam is one of the heavyweight products in the field of Enhua Pharmaceuticals psycho-tranquiliasis, in 2019 China's public medical institutions terminal for enterprises to bring nearly 20% sales contribution rate Figure 4: Sales of Midazolam (in units: 10,000 yuan) In 2019, in China's public medical institutions terminal chemical drug psychostable drug generic name TOP20, Midazolam ranked TOP6 with sales of nearly 630 million yuan, a growth rate of 17.74 percent, the leading enterprise Enhua Pharmaceuticals market share of 79.20 percent Enhua Pharmaceuticals involved in the products of Midaazole tablets and Medaaaazole injections, if the hydrochloric acid Midaazolam syrup 3 types of generic listing application signed, that is, for the domestic first imitation and as review, for the enterprise in the market competition to add new momentum, the current Enda Pharmaceuticals Midazolam injection consistency evaluation is being reviewed Table 4: Application for listing of internal sedatives in review from 2020 to now
    From 2020 to the present, in addition to Enhua Pharmaceuticals hydrochloric acid Midazolam syrup 3 types of imitation listing application, Beijing Chengji Pharmaceutical's left ethyl Lasitan oral solution 4 imitation listing application has been accepted, involving the internal service solution agent 13 acceptance numbers are still in the review and approval, two of which are imported 5.1 categories domestic imitation, Chengdu Bete Pharmaceuticals and Xintai Pharmaceuticals (Suzhou) in the competition for oseltamivir dry suspension of phosphate domestic first imitation; Earlier has been Shandong Dain Marine Biopharma declaration 6 categories of imitation, CDE in 2018 to give the review recommendations for information, a magenta can finally take the first imitation, we wait and see; in the consistency evaluation supplement application, Hainan Puli Pharmaceutical's ground chlorate dry suspension, The National Pharmaceutical Group Shantou Jinshi Pharmaceutical's head spore propaean dry suspension, and Hainan Sanye Good Pharma's cephalosporine ester dry suspension agent is being reviewed and approved Original title: solution agent market first broke 20 billion, 3 major domestic brands skyrocketed! Enwar's heavyweight debut, Ostawe robbed
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.